AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-13 (canceled).

Claim 14. (currently amended): Method of ~~the~~in-vivo administration of drugs with binding affinity for plasma protein, which is characterized in that, in the administration of a first drug with binding affinity for plasma protein, verapamil as a ~~single or plural~~ second drug with binding affinity for the same plasma protein for which the first drug has binding affinity, is administered simultaneously with the first drug or before or after the administration of the first drug to thereby regulate the binding of the first drug to the plasma protein.

Claim 15. (previously presented): The method of the administration of drugs with binding affinity for plasma protein according to Claim 14, wherein the second drug has binding affinity to the same binding sites on plasma protein to which the first drug has binding affinity.

Claim 16. (previously presented): The method of the administration of drug with binding affinity for plasma protein according to Claim 14, wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.

Claim 17. (previously presented): The method of the administration of drugs with binding affinity for plasma protein according to Claim 15, wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.

Claim 18. (previously presented): The method of the administration of drugs with binding affinity for plasma protein according to Claim 16 or 17, wherein the radiodiagnostic

drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon (^{11}C), 15-oxygen (^{15}O), 18-fluorine (^{18}F), 32-phosphorus (^{32}P), 59-iron (^{59}Fe), 67-copper (^{67}Cu) , 67-gallium (^{67}Ga), 81m-krypton (^{81m}Kr), 81-rubidium (^{81}Rb), 89-strontium (^{89}Sr), 90-yttrium (^{90}Y), 99m-technetium (^{99m}Tc), 111-indium (^{111}In), 123-iodine (^{123}I), 125-iodine (^{125}I), 131-iodine (^{131}I), 133-xenon (^{133}Xe), 117m-tin (^{117m}Sn), 153-samarium (^{153}Sm), 186-rhenium (^{186}Re), 188-rhenium (^{188}Re), 201-thallium ($^{201}T1$), 212-bismuth (^{212}Bi), 213--bismuth (^{213}Bi) and 211-astatine (^{211}At).

Claim 19. (previously presented): The method of the administration of drugs with binding affinity for plasma protein according to Claim 16 or 17, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of a bisaminothiol compound, a monaminomonoamidobisthiol compound, a bisamidobisthiol compound, a mercaptoacetylglycylglycylglycine compound, a hexamethylpropyleneamineoxime compound, an ethylenebis [bis(2-ethoxyethyl) phosphine] compound, a 2,3-dimercaptosuccinic acid compound, an ethylenecysteine dimer compound, a methoxyisobutylisonitrile compound, a polyamine compound, a pyriodoxylydeneaminate compound, methylene diphosphonate, a hydroxymethylene diphosphonate compound, a ß-methyl-ω-phenylpentadecanoic acid compound, N-isopropylamphetamine, hippuric acid, benzylguanidine and a tropane compound.

Claim 20. (canceled).

Claim 21. (currently amended): A pharmaceutical preparation for regulating binding affinity of a first drug for plasma protein, which comprises a first drug with binding affinity for

plasma protein and verapamil as a ~~single or plural~~ second drug with binding affinity for the same plasma protein, for which the first drug has binding affinity.

Claim 22. (previously presented): The pharmaceutical preparation according to Claim 21, wherein each of the first drug and the second drug is in a separate container, and prepared as a kit.

Claim 23. (previously presented): The pharmaceutical preparation according to Claim 21, wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.

Claim 24. (previously presented): The pharmaceutical preparation according to Claim 22, wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.

Claim 25. (previously presented): The pharmaceutical preparation according to any one of Claims 21 to 24, wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.

Claim 26. (previously presented): The pharmaceutical preparation according to Claim 25, wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon (^{11}C), 15-oxygen (^{15}O), 18-fluorine (^{18}F), 32-phosphorus (^{32}P), 59-iron (^{59}Fe), 67-copper (^{67}Cu), 67-gallium (^{67}Ga), 81m-krypton (^{81m}Kr), 81-rubidium (^{81}Rb), 89-strontium (^{89}Sr), 90-yttrium (^{90}Y), 99m-technetium (^{99m}Tc), 111-indium (^{111}In), 123-iodine (^{123}I), 125-iodine (^{125}I), 131-iodine (^{131}I), 133-xenon (^{133}Xe), 117m-tin (^{117m}Sn), 153-samarium (^{153}Sm), 186-

rhenium (^{186}Re), 188-rhenium (^{188}Re), 201-thallium (^{201}Tl), 212-bismuth (^{212}Bi), 213-bismuth (^{213}Bi) and 211-astatine (^{211}At).

Claim 27. (previously presented): The pharmaceutical preparation according to Claim 25, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of a bisaminothiol compound, a monaminomonoamidobisthiol compound, a bisamidobisthiol compound, a mercaptoacetylglycylglycylglycine compound, a hexamethylpropyleneamineoxime compound, an ethylenebis [bis(2-ethoxyethyl) phosphine] compound, a 2,3-dimercaptosuccinic acid compound, an ethylenecysteine dimer compound, a methoxyisobutylisonitrile compound, a polyamine compound, a pyriodoxylydeneaminate compound, methylene diphosphonate, a hydroxymethylene diphosphonate compound, a ß-methyl-ω-phenylpentadecanoic acid compound, N-isopropylamphetamine, hippuric acid, benzylguanidine and a tropane compound..

Claims 28 and 29. (canceled).